Highlights by Yüksel Ürün from ASCO GU25 Day 1
The 2025 ASCO Genitourinary Cancers Symposium is currently taking place from February 13-15 at Moscone West in San Francisco. This event is showcasing the latest research and best practices in genitourinary (GU) cancer care, with expert talks and engaging discussions. Attendees are experiencing a comprehensive program that includes keynote presentations, panel discussions, and interactive sessions focused on advancements in the diagnosis, treatment, and patient management of GU cancers.
The symposium provides healthcare professionals with an invaluable opportunity to engage with leading researchers, gain insights into emerging therapies, and enhance their clinical practices. It is co-sponsored by the American Society of Clinical Oncology, the American Society for Radiation Oncology, and the Society of Urologic Oncology.
Yüksel Ürün, Medical Oncology Professor at Ankara University School of Medicine, shared about this conference on X:
“SBRT in Oligometastatic CRPC:
- Adding SBRT to ADT+Enza doubled rPFS and delayed time to next therapy. OS data immature but signals lower risk of death. Minimal toxicity.
- Should SBRT become standard in oligometastatic CRPC?”
Mevrometostat + Enzalutamide in mCRPC
“Mevrometostat + Enzalutamide in mCRPC: A Promising Combo?
M+E doubled rPFS vs E alone, OR rate was 27% vs 14%, and PSA50 response was 34% vs 15%.
M 875 mg + food showing better safety.
Further trials needed!”
Can Diet and Probiotics Slow PCa Progression?
“Gut-Prostate Axis: Can Diet and Probiotics Slow PCa Progression?
Adding probiotics, prebiotics, and vitamin D led to PSA decline compared to placebo. It also improved urinary and erectile function with good tolerance.”
Sharing insights on advancing GU cancer care
“Connecting with the global oncology community at GU25! Representing Türkiye and sharing insights on advancing GU cancer care. Where do you call home?”
“EMETPRO Study Metastatic hormone-sensitive prostate cancer (mHSPC) with early progression (EP) is linked to poor outcomes, regardless of 1L treatment in mCRPC. The best strategy remains an unmet need!”
Could PSA nadir be a future de-escalation marker?
“CHAARTED 10-Year Analysis PSA nadir <0.2 at 6 months predicts better long-term survival in metastatic hormone-sensitive prostate cancer (mHSPC), independent of treatment arm! Could PSA nadir be a future de-escalation marker?”
The future of GU oncology is bright
“The future of GU oncology is bright, and moments like these remind us why! Grateful to stand alongside brilliant minds Zeynep Irem Ozay and Emre Yekeduz at GU25 Mentorship, collaboration, and progress in action!”
Dr. William Dahut on driving cancer innovation
“Keynote at GU25.
Dr. William Dahut on driving cancer innovation:
- Advancing patient-centered care
- Advocating for early detection policies
- Investing in future scientists.”
Saddened by the loss of Felix Feng
“Deeply saddened by the loss of Felix Feng – a brilliant mind, a dedicated colleague, and a kind soul. His impact on oncology and the lives he touched will never be forgotten. Rest in peace, Felix. Your legacy lives on.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023